GOG 262: Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Weekly paclitaxel did not significantly extend progression-free survival (PFS) compared to every-3-week paclitaxel overall.
Study Summaries
GOG 172: Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
IP administration of cisplatin and paclitaxel significantly improves both progression-free and overall survival in patients with optimally debulked stage III ovarian cancer compared to standard IV therapy, despite increased toxicities.
GOG 158: Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer
The combination of carboplatin and paclitaxel is not inferior to cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. Carboplatin plus paclitaxel results in less toxicity and is easier to administer.
InnovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab Vedotin for Recurrent Cervical Cancer
Second- or third-line treatment with tisotumab vedotin significantly improves overall survival and progression-free survival compared to chemotherapy in patients with recurrent cervical cancer.
CHORUS Trial: PDS vs. NACT
Primary chemotherapy followed by delayed surgery is non-inferior to primary surgery followed by chemotherapy in women with advanced ovarian cancer, with reduced surgical morbidity and mortality.
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer: EORTC Trial
Neoadjuvant chemotherapy followed by interval debulking surgery is not inferior to primary debulking surgery followed by chemotherapy in patients with bulky stage IIIC or IV ovarian carcinoma. Complete resection of all macroscopic disease remains the objective in cytoreductive surgery.
Early Stage Ovarian Cancer Trials List
ACTION Trial - Early Stage Ovarian 10 year
Completeness of surgical staging is a significant prognostic factor, with better outcomes observed in optimally staged patients. Adjuvant chemotherapy benefits appear restricted to nonoptimally staged patients.
Tisotumab in Cervical Cancer: InnovaTV 204/ GOG-3023/ENGOT-cx6 Phase 2 trial
Tisotumab vedotin showed clinically meaningful and durable antitumor activity with a manageable and tolerable safety profile in women with previously treated recurrent or metastatic cervical cancer.
GOG 240: Bevacizumab in Advanced Cervical Cancer
The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer improved median overall survival by 3.7 months and was associated with higher response rates.